Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of +80.51% compared to a loss of $0.44 per share a year ago [1][2] Financial Performance - The company posted revenues of $290.38 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.21% and showing an increase from $252.45 million in the same quarter last year [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus revenue estimates four times [2] Stock Performance - Shares of Tandem Diabetes Care have declined approximately 13.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.45 on revenues of $249.96 million, and for the current fiscal year, it is -$0.99 on revenues of $1.1 billion [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock performance [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]